Evidence map›Paper›PMID 42763982›Full record

ArticleHematology, transfusion and cell therapy2026

Melatonin potentiates the antineoplastic effects of venetoclax in acute myeloid leukemia cells.

Vahid Vahedian, Keli Lima, Bruna Oliveira de Almeida, Rita de Cássia Cavaglieri, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vahid VahedianLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Clinical Medicine, Division of Hematology and Hemotherapy, Faculty of Medicine, University of São Paulo, São Paulo, Brazil; DO'r Institute for Education and Research (IDOR), Sao Paulo, Brazil.
Keli LimaLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Clinical Medicine, Division of Hematology and Hemotherapy, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Bruna Oliveira de AlmeidaDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil.
Rita de Cássia CavaglieriLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Clinical Medicine, Division of Hematology and Hemotherapy, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil. Electronic address: jamachadoneto@usp.br.
Eduardo Magalhães RegoLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Clinical Medicine, Division of Hematology and Hemotherapy, Faculty of Medicine, University of São Paulo, São Paulo, Brazil; DO'r Institute for Education and Research (IDOR), Sao Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42763982
PMCPMC13628242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.